September 20, 2018. NCHR Testimony on Pediatric Advisory Committee Meeting for drugs Lexapro, Intuniv and Desferasirox. This meeting was to go over the safety profiles of the aforementioned drugs, label profiles as well as recent clinical studies done.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Summary of Published Study by MD Anderson Physicians on the Increase in Rare Diseases Among Women with Breast Implants
September 17, 2018. We summarize the study conducted by MD Anderson Cancer Center regarding the incidence of rare diseases among women with breast implants.
Read More »NCHR Comments on the FDA’s Experimental Study of Risk Information Amount and Location in Direct-To-Consumer Print Ads
The NCHR makes comments to the FDA on an experimental study that examines the way consumers look at the location of risk information for drugs in print-ads.
Read More »NCHR Comments on FDA’s Draft Guidance on Patient-Focused Drug Development
September 11, 2018. We support FDA’s efforts to increase patient engagement and input into medical product development and testing. However, we recognize how challenging it is to ensure that the information will reflect the views and experiences of a representative sample of patients. That challenge must be met in order to develop treatments that have a more meaningful impact on patients’ lives with risks that patients consider acceptable.
Read More »NCHR’s Comments to EPA on Problem Formulations for Risk Evaluations under TSCA for Ten Chemicals
August 16, 2018. We oppose the EPA’s proposed “problem formulations” because they would not adequately evaluate exposure, harm or risk. They would exclude many of the uses, exposures, and hazards that would have been included in the risk evaluations that were planned as part of the scoping documents.
Read More »